CINA CHEST vs AVIEW
AI Verdict
Choose CINA CHEST if…
Choose CINA CHEST if your primary need is rapid, AI-powered triage and notification for acute, life-threatening chest conditions in an emergency setting. This tool is ideal for quickly identifying suspected Pulmonary Embolism or Aortic Dissection on CT angiography scans to prioritize critical cases and streamline emergency radiology workflows.
View CINA CHEST →Choose AVIEW if…
Choose AVIEW if you require a comprehensive AI platform for the early detection, diagnosis, and long-term monitoring of chronic lung diseases and cardiovascular risk. This solution excels in detailed lung nodule characterization, emphysema quantification, and coronary artery calcium scoring, making it suitable for lung cancer screening programs and chronic disease management.
View AVIEW →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | CINA CHEST | AVIEW |
|---|---|---|
| Pricing | Subscription-based | Subscription; one-off payment |
| Deployment | Cloud-based, On-premise (dedicated hardware), Virtualized (VM, Docker) | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| FDA Status | K210237 AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEWTool B (AVIEW) offers a more comprehensive and integrated user experience with features like 3D visualizations, comprehensive PDF reports, and workflow automation with PACS/RIS/CIS integration. Recent upgrades in UI/UX and demonstrated improvements in case throughput and interpretation time for AVIEW 2.0 suggest a strong focus on streamlining a broader range of radiology tasks.
Clinical Value
CINA CHESTWhile both tools offer significant clinical value, Tool A (CINA CHEST) focuses on the rapid detection and prioritization of acute, life-threatening conditions like Pulmonary Embolism (PE) and Aortic Dissection (AD). Its FDA clearance and strong standalone performance in clinical studies for these emergency conditions highlight its immediate critical impact on patient outcomes in time-sensitive situations.
Pricing & Value
AVIEWTool B (AVIEW) provides greater transparency and flexibility in its pricing model, offering both subscription and one-off payment options based on installations and users. Furthermore, Coreline Soft has achieved a significant milestone by securing a US billing code for its AVIEW CAC solution, directly addressing reimbursement and demonstrating a clear path to value realization for healthcare providers.
Enterprise Readiness
AVIEWTool B (AVIEW) demonstrates superior enterprise readiness with multiple FDA clearances for its various modules, explicit GDPR compliance, and ISO 27001 certification, in addition to HIPAA compliance. Its deployment options include a 'Hybrid solution' and the AVIEW HUB platform is designed for managing complex multisite workflows and GDPR-compliant data handling, offering robust flexibility and security for large organizations.
Innovation
AVIEWTool B (AVIEW) exhibits a broader and deeper range of innovative features, including comprehensive multi-disease analysis from a single scan, advanced quantification, 3D visualizations, and an integrated diagnostic ecosystem (AVIEW 2.0) that moves beyond task-specific tools. Its extensive patent portfolio and continuous development of new modules for a wider array of diagnostic challenges underscore its strong commitment to ongoing innovation.
Support & Docs
TieNeither the provided structured facts nor the web search results offered sufficient specific details regarding the quality, availability, or comprehensiveness of support channels, service level agreements, or extensive publicly available documentation for either Tool A or Tool B. Both companies appear to have general information and clinical publications, but no distinguishing factors for this dimension were found.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CINA CHEST | AVIEW |
|---|---|---|
| Company | Avicenna.AI | Coreline Soft Co. |
| Product Name | CINA CHEST | AVIEW |
| Description | CINA CHEST is an FDA-cleared AI-powered radiological triage and notification software by Avicenna.AI, designed for the rapid detection and prioritization of Pulmonary Embolism (PE) and Aortic Dissection (AD) on CT angiography scans. | Coreline Soft's AVIEW AI platform offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, enhancing diagnostic precision and streamlining radiology workflows. |
| Key Detections/Analysis | Pulmonary Embolism (PE) on Chest CT angiography, Aortic Dissection (AD) on Chest or Thoraco-abdominal CT angiography | Lung nodule detection and characterization, Emphysema quantification and low attenuation area (LAA) analysis, Coronary artery calcium (CAC) scoring, Automated segmentation of lung lobes, airways, vessels, and coronary arteries, Interstitial Lung Disease (ILD) pattern analysis |
| Specialties | Cardiology, Emergency Medicine, Radiology | Cardiology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring CINA CHEST and AVIEW.